JSC Farmak will meet its output target by the end of 2020, anticipates Farmak Executive Director Volodymyr Kostiuk.
“We do not expect to go into the red this year. We will have probably get what we planned by the end of the year,” he said to Interfax-Ukraine on the sidelines of the presentation of Ukraine’s first mobile pharmaceutical museum.
Kostiuk believes that the implementation of the target indicators will be achieved, in particular, due to increased exports.
“In particular, we managed to export to other countries a lot. The Ukrainian market has contracted,” he stated.
Kostiuk noted that during the quarantine nearly 400 employees worked remotely with their salary paid in full.
“At the height of the quarantine 400 employees worked remotely. Now there are slightly fewer of them, but we are gradually increasing this number due to the worsening epidemical situation and a growing number of COVID cases. All employees on remote work receive full salaries,” he said.
Kostiuk also said that with the beginning of the coronavirus pandemic, Farmak started producing antiseptic for the company’s needs.
“We developed it very quickly basing on WHO formula to meet our company needs. We do not produce it now,” he said.
Kostiuk also said Farmak continues clinical trials on the effectiveness of the company’s Amizon drug in treating COVID-19 infected patients.
Farmak is the leader of the Ukrainian pharmaceutical market with a 5.9% stake in monetary terms.
Over the past five years, Farmak’s investments in the scientific and technical complex, production equipment and research activities amounted to UAH 3.4 billion.